首页 > 最新文献

Kidney International Supplements最新文献

英文 中文
Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes 捕获和监测未治疗和治疗的终末期肾脏疾病、肾脏替代治疗方式和结果的全球差异
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2020-03-01 DOI: 10.1016/j.kisu.2019.11.001
Roberto Pecoits-Filho , Ikechi G. Okpechi , Jo-Ann Donner , David C.H. Harris , Harith M. Aljubori , Aminu K. Bello , Ezequiel Bellorin-Font , Fergus J. Caskey , Allan Collins , Alfonso M. Cueto-Manzano , John Feehally , Bak Leong Goh , Kitty J. Jager , Masaomi Nangaku , Muhibur Rahman , Manisha Sahay , Abdulkarim Saleh , Laura Sola , Rumeyza Turan Kazancioglu , Rachael C. Walker , David W. Johnson

A large gap between the number of people with end-stage kidney disease (ESKD) who received kidney replacement therapy (KRT) and those who needed it has been recently identified, and it is estimated that approximately one-half to three-quarters of all people with ESKD in the world may have died prematurely because they could not receive KRT. This estimate is aligned with a previous report that estimated that >3 million people in the world died each year because they could not access KRT. This review discusses the reasons for the differences in treated and untreated ESKD and KRT modalities and outcomes and presents strategies to close the global KRT gap by establishing robust health information systems to guide resource allocation to areas of need, inform KRT service planning, enable policy development, and monitor KRT health outcomes.

最近发现,接受肾脏替代治疗(KRT)的终末期肾病(ESKD)患者与需要肾脏替代治疗的患者之间存在巨大差距,据估计,全世界约有一半至四分之三的ESKD患者可能因无法接受KRT而过早死亡。这一估计与之前的一份报告一致,该报告估计,世界上每年有300万人因无法获得KRT而死亡。本综述讨论了治疗和未治疗ESKD和KRT模式和结果差异的原因,并提出了通过建立健全的卫生信息系统来缩小全球KRT差距的策略,以指导资源分配到需要的地区,为KRT服务规划提供信息,促进政策制定,并监测KRT健康结果。
{"title":"Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes","authors":"Roberto Pecoits-Filho ,&nbsp;Ikechi G. Okpechi ,&nbsp;Jo-Ann Donner ,&nbsp;David C.H. Harris ,&nbsp;Harith M. Aljubori ,&nbsp;Aminu K. Bello ,&nbsp;Ezequiel Bellorin-Font ,&nbsp;Fergus J. Caskey ,&nbsp;Allan Collins ,&nbsp;Alfonso M. Cueto-Manzano ,&nbsp;John Feehally ,&nbsp;Bak Leong Goh ,&nbsp;Kitty J. Jager ,&nbsp;Masaomi Nangaku ,&nbsp;Muhibur Rahman ,&nbsp;Manisha Sahay ,&nbsp;Abdulkarim Saleh ,&nbsp;Laura Sola ,&nbsp;Rumeyza Turan Kazancioglu ,&nbsp;Rachael C. Walker ,&nbsp;David W. Johnson","doi":"10.1016/j.kisu.2019.11.001","DOIUrl":"10.1016/j.kisu.2019.11.001","url":null,"abstract":"<div><p><span>A large gap between the number of people with end-stage kidney disease (ESKD) who received kidney replacement therapy (KRT) and those who needed it has been recently identified, and it is estimated that approximately one-half to three-quarters of all people with ESKD in the world may have died prematurely because they could not receive KRT. This estimate is aligned with a previous report that estimated that &gt;3 million people in the world died each year because they could not access KRT. This review discusses the reasons for the differences in treated and untreated ESKD and KRT modalities and outcomes and presents strategies to close the global KRT gap by establishing robust </span>health information systems to guide resource allocation to areas of need, inform KRT service planning, enable policy development, and monitor KRT health outcomes.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 1","pages":"Pages e3-e9"},"PeriodicalIF":5.5,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2019.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37718558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 37
Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis 制定血液透析和腹膜透析最低和最佳安全和质量标准框架
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2020-03-01 DOI: 10.1016/j.kisu.2019.11.009
Laura Sola , Nathan W. Levin , David W. Johnson , Roberto Pecoits-Filho , Harith M. Aljubori , Yuqing Chen , Stefaan Claus , Allan Collins , Brett Cullis , John Feehally , Paul N. Harden , Mohamed H. Hassan , Fuad Ibhais , Kamyar Kalantar-Zadeh , Adeera Levin , Abdulkarim Saleh , Daneil Schneditz , Irma Tchokhonelidze , Rumeyza Turan Kazancioglu , Ahmed Twahir , Fredric O. Finkelstein

Substantial heterogeneity in practice patterns around the world has resulted in wide variations in the quality and type of dialysis care delivered. This is particularly so in countries without universal standards of care and governmental (or other organizational) oversight. Most high-income countries have developed such oversight based on documentation of adherence to standardized, evidence-based guidelines. Many low- and lower-middle-income countries have no or only limited organized oversight systems to ensure that care is safe and effective. The implementation and oversight of basic standards of care requires sufficient infrastructure and appropriate workforce and financial resources to support the basic levels of care and safety practices. It is important to understand how these standards then can be reasonably adapted and applied in low- and lower-middle-income countries.

世界各地实践模式的巨大异质性导致透析护理的质量和类型存在很大差异。在没有普遍护理标准和政府(或其他组织)监督的国家尤其如此。大多数高收入国家都建立了基于遵守标准化循证指南的文件的监督机制。许多低收入和中低收入国家没有或只有有限的有组织的监督系统,以确保护理的安全和有效。实施和监督基本护理标准需要足够的基础设施和适当的人力和财政资源,以支持基本水平的护理和安全做法。重要的是要了解如何在低收入和中低收入国家合理地调整和应用这些标准。
{"title":"Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis","authors":"Laura Sola ,&nbsp;Nathan W. Levin ,&nbsp;David W. Johnson ,&nbsp;Roberto Pecoits-Filho ,&nbsp;Harith M. Aljubori ,&nbsp;Yuqing Chen ,&nbsp;Stefaan Claus ,&nbsp;Allan Collins ,&nbsp;Brett Cullis ,&nbsp;John Feehally ,&nbsp;Paul N. Harden ,&nbsp;Mohamed H. Hassan ,&nbsp;Fuad Ibhais ,&nbsp;Kamyar Kalantar-Zadeh ,&nbsp;Adeera Levin ,&nbsp;Abdulkarim Saleh ,&nbsp;Daneil Schneditz ,&nbsp;Irma Tchokhonelidze ,&nbsp;Rumeyza Turan Kazancioglu ,&nbsp;Ahmed Twahir ,&nbsp;Fredric O. Finkelstein","doi":"10.1016/j.kisu.2019.11.009","DOIUrl":"10.1016/j.kisu.2019.11.009","url":null,"abstract":"<div><p>Substantial heterogeneity in practice patterns around the world has resulted in wide variations in the quality and type of dialysis care delivered. This is particularly so in countries without universal standards of care and governmental (or other organizational) oversight. Most high-income countries have developed such oversight based on documentation of adherence to standardized, evidence-based guidelines. Many low- and lower-middle-income countries have no or only limited organized oversight systems to ensure that care is safe and effective. The implementation and oversight of basic standards of care requires sufficient infrastructure and appropriate workforce and financial resources to support the basic levels of care and safety practices. It is important to understand how these standards then can be reasonably adapted and applied in low- and lower-middle-income countries.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 1","pages":"Pages e55-e62"},"PeriodicalIF":5.5,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2019.11.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37718563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
The role of kidney transplantation as a component of integrated care for chronic kidney disease 肾移植作为慢性肾脏疾病综合护理的一个组成部分的作用
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2020-03-01 DOI: 10.1016/j.kisu.2019.11.006
Philip J. O'Connell , Mark Brown , Tak Mao Chan , Rolando Claure-Del Granado , Simon J. Davies , Somchai Eiam-Ong , Mohamed H. Hassan , Kamyar Kalantar-Zadeh , Adeera Levin , Dominique E. Martin , Elmi Muller , Shahrzad Ossareh , Irma Tchokhonelidze , Michele Trask , Ahmed Twahir , Anthony J.O. Were , Chih-Wei Yang , Alexander Zemchenkov , Paul N. Harden

Kidney transplant provides superior outcomes to dialysis as a treatment for end-stage kidney disease. Therefore, it is essential that kidney transplantation be part of an integrated treatment and management plan for chronic kidney disease (CKD). Developing an effective national program of transplantation is challenging because of the requirement for kidney donors and the need for a multidisciplinary team to provide expert care for both donors and recipients. This article outlines the steps necessary to establish a national kidney transplant program, starting with the requirement for effective legislation that provides the legal framework for transplantation whilst protecting organ donors, their families, recipients, and staff and is an essential requirement to combat organ trafficking. The next steps involve capacity building with the development of a multiskilled workforce, the credentialing of transplant centers, and the reporting of outcomes through national or regional registries. Although it is accepted that most transplant programs will begin with living related kidney donation, it is essential to aspire to and develop a deceased donor program. This requires engagement with multiple stakeholders, especially the patients, the general community, intensivists, and health departments. Development of transplant centers should be undertaken in concert with the development of a dialysis program. Both are essential components of integrated care for CKD and both should be viewed as part of the World Health Organization’s initiative for universal health coverage. Provisions to cover the costs of treatment for patients need to be developed taking into account the state of development of the overall health framework in each country.

作为终末期肾脏疾病的治疗,肾移植提供了比透析更好的结果。因此,将肾移植作为慢性肾脏疾病(CKD)综合治疗和管理计划的一部分是至关重要的。制定一个有效的国家移植计划是具有挑战性的,因为对肾脏供体的需求和需要一个多学科团队为供体和受体提供专家护理。本文概述了建立国家肾移植计划的必要步骤,首先是需要有效的立法,为移植提供法律框架,同时保护器官捐赠者、他们的家人、接受者和工作人员,这是打击器官贩运的基本要求。接下来的步骤包括能力建设,发展一支多技能的劳动力队伍,对移植中心进行认证,并通过国家或地区登记处报告结果。虽然大多数移植项目将从生前亲属的肾脏捐赠开始,但渴望和发展一个已故捐赠者项目是必不可少的。这需要多方利益相关者的参与,特别是患者、普通社区、重症监护医生和卫生部门。移植中心的发展应与透析项目的发展相协调。两者都是慢性肾病综合护理的重要组成部分,都应被视为世界卫生组织全民健康覆盖倡议的一部分。需要考虑到每个国家整体卫生框架的发展状况,制定支付病人治疗费用的规定。
{"title":"The role of kidney transplantation as a component of integrated care for chronic kidney disease","authors":"Philip J. O'Connell ,&nbsp;Mark Brown ,&nbsp;Tak Mao Chan ,&nbsp;Rolando Claure-Del Granado ,&nbsp;Simon J. Davies ,&nbsp;Somchai Eiam-Ong ,&nbsp;Mohamed H. Hassan ,&nbsp;Kamyar Kalantar-Zadeh ,&nbsp;Adeera Levin ,&nbsp;Dominique E. Martin ,&nbsp;Elmi Muller ,&nbsp;Shahrzad Ossareh ,&nbsp;Irma Tchokhonelidze ,&nbsp;Michele Trask ,&nbsp;Ahmed Twahir ,&nbsp;Anthony J.O. Were ,&nbsp;Chih-Wei Yang ,&nbsp;Alexander Zemchenkov ,&nbsp;Paul N. Harden","doi":"10.1016/j.kisu.2019.11.006","DOIUrl":"10.1016/j.kisu.2019.11.006","url":null,"abstract":"<div><p>Kidney transplant<span><span> provides superior outcomes to dialysis as a treatment for end-stage kidney disease. Therefore, it is essential that </span>kidney transplantation<span><span> be part of an integrated treatment and management plan for chronic kidney disease (CKD). Developing an effective national program of transplantation is challenging because of the requirement for kidney donors and the need for a multidisciplinary team to provide expert care for both donors and recipients. This article outlines the steps necessary to establish a national kidney transplant program, starting with the requirement for effective legislation that provides the legal framework for transplantation whilst protecting organ donors, their families, recipients, and staff and is an essential requirement to combat organ trafficking. The next steps involve capacity building with the development of a multiskilled workforce, the credentialing of transplant centers, and the reporting of outcomes through national or regional registries. Although it is accepted that most transplant programs will begin with living related kidney donation, it is essential to aspire to and develop a deceased donor program. This requires engagement with multiple stakeholders, especially the patients, the general community, </span>intensivists, and health departments. Development of transplant centers should be undertaken in concert with the development of a dialysis program. Both are essential components of integrated care for CKD and both should be viewed as part of the World Health Organization’s initiative for universal health coverage. Provisions to cover the costs of treatment for patients need to be developed taking into account the state of development of the overall health framework in each country.</span></span></p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 1","pages":"Pages e78-e85"},"PeriodicalIF":5.5,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2019.11.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37718566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Supportive care for end-stage kidney disease: an integral part of kidney services across a range of income settings around the world 终末期肾脏疾病的支持性护理:世界各地各种收入环境中肾脏服务的组成部分
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2020-03-01 DOI: 10.1016/j.kisu.2019.11.008
Barnaby Hole , Brenda Hemmelgarn , Edwina Brown , Mark Brown , Mignon I. McCulloch , Carlos Zuniga , Sharon P. Andreoli , Peter G. Blake , Cécile Couchoud , Alfonso M. Cueto-Manzano , Gavin Dreyer , Guillermo Garcia Garcia , Kitty J. Jager , Marla McKnight , Rachael L. Morton , Fliss E.M. Murtagh , Saraladevi Naicker , Gregorio T. Obrador , Jeffrey Perl , Muhibur Rahman , Fergus J. Caskey

A key component of treatment for all people with advanced kidney disease is supportive care, which aims to improve quality of life and can be provided alongside therapies intended to prolong life, such as dialysis. This article addresses the key considerations of supportive care as part of integrated end-stage kidney disease care, with particular attention paid to programs in low- and middle-income countries. Supportive care should be an integrated component of care for patients with advanced chronic kidney disease, patients receiving kidney replacement therapy (KRT), and patients receiving non-KRT conservative care. Five themes are identified: improving information on prognosis and support, developing context-specific evidence, establishing appropriate metrics for monitoring care, clearly communicating the role of supportive care, and integrating supportive care into existing health care infrastructures. This report explores some general aspects of these 5 domains, before exploring their consequences in 4 health care situations/settings: in people approaching end-stage kidney disease in high-income countries and in low- and middle-income countries, and in people discontinuing KRT in high-income countries and in low- and middle-income countries.

所有晚期肾病患者治疗的一个关键组成部分是支持性护理,其目的是改善生活质量,并可与旨在延长生命的治疗(如透析)一起提供。本文讨论了支持治疗作为终末期肾病综合治疗的一部分的关键考虑因素,特别关注低收入和中等收入国家的项目。对于晚期慢性肾病患者、接受肾脏替代治疗(KRT)的患者和接受非KRT保守治疗的患者,支持性治疗应该是护理的一个综合组成部分。确定了五个主题:改善关于预后和支持的信息,发展针对具体情况的证据,建立监测护理的适当指标,明确宣传支持护理的作用,以及将支持护理纳入现有卫生保健基础设施。本报告探讨了这5个领域的一些一般方面,然后探讨了它们在4种卫生保健情况/环境中的后果:高收入国家和低收入和中等收入国家接近终末期肾病的人,以及高收入国家和低收入和中等收入国家停止KRT治疗的人。
{"title":"Supportive care for end-stage kidney disease: an integral part of kidney services across a range of income settings around the world","authors":"Barnaby Hole ,&nbsp;Brenda Hemmelgarn ,&nbsp;Edwina Brown ,&nbsp;Mark Brown ,&nbsp;Mignon I. McCulloch ,&nbsp;Carlos Zuniga ,&nbsp;Sharon P. Andreoli ,&nbsp;Peter G. Blake ,&nbsp;Cécile Couchoud ,&nbsp;Alfonso M. Cueto-Manzano ,&nbsp;Gavin Dreyer ,&nbsp;Guillermo Garcia Garcia ,&nbsp;Kitty J. Jager ,&nbsp;Marla McKnight ,&nbsp;Rachael L. Morton ,&nbsp;Fliss E.M. Murtagh ,&nbsp;Saraladevi Naicker ,&nbsp;Gregorio T. Obrador ,&nbsp;Jeffrey Perl ,&nbsp;Muhibur Rahman ,&nbsp;Fergus J. Caskey","doi":"10.1016/j.kisu.2019.11.008","DOIUrl":"10.1016/j.kisu.2019.11.008","url":null,"abstract":"<div><p><span>A key component of treatment<span> for all people with advanced kidney disease is supportive care, which aims to improve </span></span>quality of life<span><span> and can be provided alongside therapies intended to prolong life, such as dialysis. This article addresses the key considerations of supportive care as part of integrated end-stage kidney disease care, with particular attention paid to programs in low- and middle-income countries. Supportive care should be an integrated component of care for patients with advanced chronic kidney disease, patients receiving </span>kidney replacement therapy<span> (KRT), and patients receiving non-KRT conservative care. Five themes are identified: improving information on prognosis and support, developing context-specific evidence, establishing appropriate metrics for monitoring care, clearly communicating the role of supportive care, and integrating supportive care into existing health care infrastructures. This report explores some general aspects of these 5 domains, before exploring their consequences in 4 health care situations/settings: in people approaching end-stage kidney disease in high-income countries and in low- and middle-income countries, and in people discontinuing KRT in high-income countries and in low- and middle-income countries.</span></span></p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 1","pages":"Pages e86-e94"},"PeriodicalIF":5.5,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2019.11.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37718567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Subscription Information 订阅信息
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2020-03-01 DOI: 10.1016/S2157-1716(20)30002-2
{"title":"Subscription Information","authors":"","doi":"10.1016/S2157-1716(20)30002-2","DOIUrl":"https://doi.org/10.1016/S2157-1716(20)30002-2","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 1","pages":"Page A2"},"PeriodicalIF":5.5,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72060674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription Information 订阅信息
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2019-03-01 DOI: 10.1016/S2157-1716(19)30002-4
{"title":"Subscription Information","authors":"","doi":"10.1016/S2157-1716(19)30002-4","DOIUrl":"https://doi.org/10.1016/S2157-1716(19)30002-4","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"9 1","pages":"Page A2"},"PeriodicalIF":5.5,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(19)30002-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72103114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Page 标题页
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2019-03-01 DOI: 10.1016/S2157-1716(19)30003-6
{"title":"Title Page","authors":"","doi":"10.1016/S2157-1716(19)30003-6","DOIUrl":"https://doi.org/10.1016/S2157-1716(19)30003-6","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"9 1","pages":"Page A3"},"PeriodicalIF":5.5,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(19)30003-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72103115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
China Kidney Disease Network (CK-NET) 2015 Annual Data Report 中国肾脏病网络(CK-NET)2015年度数据报告。
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2019-03-01 DOI: 10.1016/j.kisu.2018.11.001
Luxia Zhang (Chief Editor), Ming-Hui Zhao (Chief Editor), Li Zuo (Associate Editor), Yue Wang (Associate Editor), Feng Yu (Associate Editor), Hong Zhang (Associate Editor), Haibo Wang (Associate Editor)
{"title":"China Kidney Disease Network (CK-NET) 2015 Annual Data Report","authors":"Luxia Zhang (Chief Editor),&nbsp;Ming-Hui Zhao (Chief Editor),&nbsp;Li Zuo (Associate Editor),&nbsp;Yue Wang (Associate Editor),&nbsp;Feng Yu (Associate Editor),&nbsp;Hong Zhang (Associate Editor),&nbsp;Haibo Wang (Associate Editor)","doi":"10.1016/j.kisu.2018.11.001","DOIUrl":"10.1016/j.kisu.2018.11.001","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"9 1","pages":"Pages e1-e81"},"PeriodicalIF":5.5,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2018.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 77
KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease KDIGO 2018慢性肾脏病丙型肝炎预防、诊断、评估和治疗临床实践指南。
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2018-10-01 DOI: 10.1016/j.kisu.2018.06.001
Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group
{"title":"KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease","authors":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group","doi":"10.1016/j.kisu.2018.06.001","DOIUrl":"10.1016/j.kisu.2018.06.001","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 3","pages":"Pages 91-165"},"PeriodicalIF":5.5,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2018.06.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36891319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 119
Subscription Information 订阅信息
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2018-10-01 DOI: 10.1016/S2157-1716(18)30009-1
{"title":"Subscription Information","authors":"","doi":"10.1016/S2157-1716(18)30009-1","DOIUrl":"10.1016/S2157-1716(18)30009-1","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 3","pages":"Page A2"},"PeriodicalIF":5.5,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2157171618300091/pdfft?md5=3749e8c7a8ab9c2f875ad45d6bbbfec8&pid=1-s2.0-S2157171618300091-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47381885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney International Supplements
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1